Vincerx PharmaVINC
13F holders, Q1 2025 (March 31)At the end of Q1 2025, 14 institutions reported holding Vincerx Pharma Inc. (VINC) in their 13F filings, up 13 from Q4 2024. 4 opened new positions and 0 sold out. The largest holders were Sage Rhino Capital LLC ($45K), Citadel Advisors ($23K) and Goldman Sachs Group Inc. ($17K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Vincerx Pharma Inc.
- CUSIP
- 92731L304
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $36K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 74,837 shares bought and 5,450 shares sold, net +69,388 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Sage Rhino Capital LLC | 0.01% | No change | 85,170 | $45K |
| Citadel Advisors | 0.00% | New | 42,777 | $23K |
| Goldman Sachs Group Inc. | 0.00% | No change | 31,567 | $17K |
| Geode Capital Management, LLC | 0.00% | Add +59.7% | 19,285 | $10K |
| Vanguard Group Inc. | 0.00% | No change | 14,317 | $8K |
| Two Sigma Securities, LLC | 0.00% | New | 11,053 | $6K |
| Millennium Management | 0.00% | New | 10,798 | $6K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 2,997 | $2K |
| BlackRock, Inc. | 0.00% | No change | 2,352 | $1K |
| UBS Group AG | 0.00% | Reduce -96.9% | 142 | $75 |
| Morgan Stanley | 0.00% | Reduce -2.4% | 102 | $54 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -95.0% | 50 | $26 |
| Bank of America Corp. | 0.00% | Add +26.6% | 15 | $8 |
| JPMorgan Chase & Co. | 0.00% | Reduce -13.0% | 1 | $1 |
"% of holder's portfolio" is VINC's weight in each manager's 13F, not the share of Vincerx Pharma Inc. the manager owns.